Autopsy report · NCT01275612
Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers
Cause of deathSlow enrollment
“Patients evaluated so far could not be enrolled because they did not meet the primary criterion of acute renal failure provided by the study protocol”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 1
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Sponsor type
- University, hospital or other
- Conditions
- Solid Tumors; Acute Kidney Injury
- Interventions
- Mesenchymal stromal cell infusion
- Participants
- 0
- Sites
- 1
- Countries
- Italy
Trials that died the same way
- RCT Between UPP and Controls in Adult OSA
“No patients have been enrolled, and will not. The study was never started” - Study of Image-Guided SBRT for Vertebral Metastases
“not sufficient patients enrolled” - Continuous Thetaburst Stimulation for the Treatment of Refractory Epilepsy - Safety, Feasibility and Proof-of-concept
“Difficulty identifying and including eligible patients” - Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain
“Difficulty identifying and enrolling eligible patients” - A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma
“Suitable patients were not recruited”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.